Emma M Tillman

Dr. Emma M Tillman

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 March 2021 in Cancers
Verified
Journal Article
Open access
PDF file
Ryan NelsonRyan Nelson
Ryan Nelson
NSNathan Seligson
Nathan Seligson
SBSalvatore Bottiglieri
Salvatore Bottiglieri
ECEstrella Carballido
Estrella Carballido
ACAlex del Cueto
Alex del Cueto
J Kevin HicksJ Kevin Hicks
J Kevin Hicks
Multi-gene assays often include UGT1A1 and, in certain instances, may report associated toxicity risks for irinotecan, belinostat, pazopanib, and nilotinib. However, guidance for incorporating UGT1A1 results into therapeutic decision-making is mostly lacking for these anticancer drugs. We summarized meta-analyses, genome-wide association studies, clinical trials, drug labels, and guidelines relating to the impact of UGT1A1 polymorphisms on irinotecan, belinostat, pazopanib, or nilotinib toxicities. For irinotecan, UGT1A1*28 was significantly associated with neutropenia and diarrhea, particularly with doses ≥ 180 mg/m2, supporting the use of UGT1A1 to guide irinotecan prescribing. The drug label for belinostat recommends a reduced starting dose of 750 mg/m2 for UGT1A1*28 homozygotes, though published studies supporting this recommendation are sparse. There was a correlation between UGT1A1 polymorphisms and pazopanib-induced hepatotoxicity, though further studies are needed to elucidate the role of UGT1A1-guided pazopanib dose adjustments. Limited studies have investigated the association between UGT1A1 polymorphisms and nilotinib-induced hepatotoxicity, with data currently insufficient for UGT1A1-guided nilotinib dose adjustments.

5 August 2025 in Journal of Cystic Fibrosis
Verified
Journal Article
Open access
SSSylvia Szentpetery
Sylvia Szentpetery
DRDara Riva
Dara Riva
YBYair J. Blumenfeld
Yair J. Blumenfeld
JEJohn F. Engelhardt
John F. Engelhardt
CLCarmen Luna-Paredes
Carmen Luna-Paredes
Jennifer L TaylorJennifer L Taylor
Jennifer L Taylor
Data from cystic fibrosis (CF) animal models and case studies suggests that in utero administration of CF transmembrane conductance regulator (CFTR) modulators (variant specific therapies, VST) can rescue CFTR-related pathophysiology in the fetus. Use of VST during pregnancy to prevent disease in infants has not been systematically studied. Through stakeholder engagement, we sought to determine if formal research evaluation is warranted. We surveyed CF care center directors to assess their awareness of the potential off-label use of VST for in utero treatment of a fetus with CF. We then conducted a one-day, international multidisciplinary workshop to review available pre-clinical and clinical data, embryology principles and federal drug regulation considerations, identify knowledge gaps, and consider future clinical study designs. Sixty-two unique individuals responded to the survey; 92% were aware of use of VST to treat pregnant females who are CF carriers for the prevention of CF complications in the fetus. Expert workshop presentations suggested that use of VST in pregnant females carrying a fetus with CF to mitigate complications of CF is relatively safe and effective in animal models and human case series to date. Further research is needed to understand the optimal timing of VST initiation during pregnancy to improve clinical outcomes, to understand VST pharmacokinetics, and optimize dosing of VST during pregnancy and lactation, and to evaluate the long-term infant safety among those exposed to VST in utero. Based on available data and knowledge gaps, stakeholders agreed that formal evaluation of in utero and early life VST therapy in a prospective trial is warranted.

25 November 2024 in Journal of Cystic Fibrosis
Verified
Journal Article
Open access
CBCj Bathgate
Cj Bathgate
DFDA Fedele
DA Fedele
ETEmma M Tillman
Emma M Tillman
JHJ He
J He
RERs Everhart
Rs Everhart
AGAm Georgiopoulos
Am Georgiopoulos
This report summarizes the 2023 inaugural annual meeting of the Cystic Fibrosis Foundation's Prioritizing Research in Mental Health (PRIME) working group. This workshop focused on mental health and elexacaftor/tezacaftor/ivacaftor (ETI). We reviewed existing literature and identified key gaps and study design considerations in preclinical work, pharmacokinetics/pharmacodynamics, mood/anxiety, quality of life/self-perception, neuropsychological symptoms, sleep, and symptom management. Limited studies have identified behavioral changes with modulator exposure in rodent models of depression, anxiety, and cognition. Longitudinal human studies reporting mean changes generally show no change or improvement. However, case reports and single-center studies identify subgroups reporting new or worsening symptoms. Future studies should focus on understanding the role of CFTR in the nervous system, defining ETI impacts in preclinical models, and mechanistic investigations. Innovative methods with larger samples and comprehensive assessments are needed to determine the incidence of new/worsening symptoms throughout the lifespan and effective management strategies.

27 November 2024 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Open access
GSGerald Chun-To So
Gerald Chun-To So
JLJessica Bo Li Lu
Jessica Bo Li Lu
SKSachiko Koyama
Sachiko Koyama
YCYing‐Hua Cheng
Ying‐Hua Cheng
DGDebora L. Gisch
Debora L. Gisch
MEMichael Eadon
Michael Eadon
One in six Americans uses cannabidiol‐based or cannabis‐derived products. Cannabidiol is a substrate of CYP3A, but its role as a potential CYP3A inhibitor remains unclear. We hypothesized that cannabidiol would inhibit CYP3A‐mediated metabolism of tacrolimus. This report is an interim analysis of an open‐label, three‐period, fixed‐sequence, crossover study in healthy participants. Participants first received a single dose of tacrolimus 5 mg orally. After washout, participants later received cannabidiol titrated to 5 mg/kg twice daily for 14 days to reach a steady state, followed by a second single dose of tacrolimus 5 mg orally. Tacrolimus concentrations in whole blood were measured by UHPLC–MS/MS method. Pharmacokinetic parameters were calculated by noncompartmental analysis. Twelve participants completed all periods of the study. The maximum concentration (Cmax) of tacrolimus increased 4.2‐fold (P < 0.0001) with cannabidiol (40.2 ± 13.5 ng/mL) compared with without cannabidiol (9.85 ± 4.63 ng/mL). The area under the concentration‐vs.‐time curve (AUC0‐∞) increased 3.1‐fold (P < 0.0001). No change in half‐life (t1/2) was observed. This study demonstrates that cannabidiol increases tacrolimus exposure. Our data suggest the need for dose reduction in tacrolimus and frequent therapeutic dose monitoring in transplant patients taking cannabidiol concomitantly. Whether this observed interaction occurred due to the inhibition of CYP3A4 and/or CYP3A5 in the liver, intestine, or both, or intestinal drug transporters (e.g., p‐glycoprotein) during the first‐pass elimination remains to be elucidated.

9 August 2020 in The Journal of Clinical Pharmacology
Verified
Journal Article
Closed access
PDF file
ETEmma M Tillman
Emma M Tillman
SSSarah L. Suppes
Sarah L. Suppes
KFKeith Feldman
Keith Feldman
JGJennifer L. Goldman
Jennifer L. Goldman

25 January 2023 in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
Verified
Journal Article
Open access
SQSara K. Quinney
Sara K. Quinney
RBRobert R. Bies
Robert R. Bies
SGShaun J. Grannis
Shaun J. Grannis
CBChristopher W. Bartlett
Christopher W. Bartlett
EMEneida Mendonca
Eneida Mendonca
LLLang Li
Lang Li
Maternal and pediatric populations have historically been considered “therapeutic orphans” due to their limited inclusion in clinical trials. Physiologic changes during pregnancy and lactation and growth and maturation of children alter pharmacokinetics (PK) and pharmacodynamics (PD) of drugs. Precision therapy in these populations requires knowledge of these effects. Efforts to enhance maternal and pediatric participation in clinical studies have increased over the past few decades. However, studies supporting precision therapeutics in these populations are often small and, in isolation, may have limited impact. Integration of data from various studies, for example through physiologically based pharmacokinetic/pharmacodynamic (PBPK/PD) modeling or bioinformatics approaches, can augment the value of data from these studies, and help identify gaps in understanding. To catalyze research in maternal and pediatric precision therapeutics, the Obstetric and Pediatric Pharmacology and Therapeutics Branch of the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) established the Maternal and Pediatric Precision in Therapeutics (MPRINT) Hub. Herein, we provide an overview of the status of maternal–pediatric therapeutics research and introduce the Indiana University‐Ohio State University MPRINT Hub Data, Model, Knowledge and Research Coordination Center (DMKRCC), which aims to facilitate research in maternal and pediatric precision therapeutics through the integration and assessment of existing knowledge, supporting pharmacometrics and clinical trials design, development of new real‐world evidence resources, educational initiatives, and building collaborations among public and private partners, including other NICHD‐funded networks. By fostering use of existing data and resources, the DMKRCC will identify critical gaps in knowledge and support efforts to overcome these gaps to enhance maternal–pediatric precision therapeutics.